Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Hirokazu Shoji"'
Autor:
Toru Kadono, Satoru Iwasa, Kengo Nagashima, Kotoe Oshima, Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku
Publikováno v:
Cancer Medicine. 12:9322-9331
Autor:
Masahiko Aoki, Shigenori Kadowaki, Naoki Takahashi, Takeshi Suzuki, Kotoe Oshima, Takayuki Ando, Yoshiyuki Yamamoto, Kentaro Kawakami, Yosuke Kito, Toshihiko Matsumoto, Keitaro Shimozaki, Yasuhiro Miyazaki, Toshifumi Yamaguchi, Michitaka Nagase, Takao Tamura, Yusuke Amanuma, Taito Esaki, Yuji Miura, Kohei Akiyoshi, Eishi Baba, Akitaka Makiyama, Yuji Negoro, Koji Nakashima, Naotoshi Sugimoto, Kengo Nagashima, Hirokazu Shoji, Narikazu Boku
Publikováno v:
Gastric Cancer. 26:132-144
Background Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However, progression of non-measurable lesions and new lesions are frequently observed in patients with ad
Autor:
Daisuke Takahari, Hitoshi Katai, Atsuo Takashima, Naoki Izawa, Naoki Ishizuka, Manabu Ohashi, Shinya Mikami, Takeru Wakatsuki, Izuma Nakayama, Keisho Chin, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Satoru Iwasa, Hirokazu Shoji, Takeyuki Wada, Ayako Doi, Takaki Yoshikawa, Takeshi Sano, Narikazu Boku, Kensei Yamaguchi
Publikováno v:
Gastric Cancer.
Background We investigated the feasibility of perioperative chemotherapy with S-1 and leucovorin (TAS-118) plus oxaliplatin in patients with locally advanced gastric cancer. Methods Patients with clinical T3–4N1–3M0 gastric cancer received four c
Autor:
Haruhiko Fukuda, Akiko Hasegawa, Hitoshi Mizutani, Hirokazu Shoji, Tatsuya Takenouchi, Tetsuya Hamaguchi, Taro Shibata, Naoya Yamazaki, Tomohiro Nishina, Keiko Nozawa, Atsuo Takashima, Toshiki Masuishi, Narikazu Boku, Shusuke Yoshikawa, Akihito Kawazoe, Sumiko Takatsuka, Ryunosuke Machida, Yoshio Kiyohara, Katsuko Kikuchi, Masanobu Takahashi
Publikováno v:
Supportive Care in Cancer. 30:4497-4504
Background: Althoughpre-emptive therapy with oral tetracycline, moisturizer, sunscreen and topical corticosteroid isuseful for preventing acneiform eruption (AfE) due to epidermal growth factor receptor (EGFR) inhibitors, no studies have examinedthe
Autor:
Yoshitaka Honma, Hidekazu Hirano, Satoru Iwasa, Hirokazu Shoji, Ken Kato, Shigemasa Takamizawa, Narikazu Boku, Natsuko Okita, Atsuo Takashima, Shun Yamamoto, Koji Izutsu
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 85-89 (2021)
Case Reports in Oncology
Case Reports in Oncology
Severe thrombocytopenia is a rare adverse event of panitumumab. Here, we report the first patient with metastatic colorectal cancer who developed severe thrombocytopenia, diagnosed as panitumumab-associated drug-induced immune thrombocytopenia (DITP)
Autor:
Toru Kadono, Satoru Iwasa, Hidekazu Hirano, Hirokazu Shoji, Natsuko Okita Okita, Atsuo Takashima, Ken Kato
Publikováno v:
Journal of Clinical Oncology. 41:322-322
322 Background: Ramucirumab (RAM), nivolumab (NIVO), and trifluridine/tipiracil (FTD/TPI) were approved for advanced gastric cancer (AGC) between 2010 and 2020 in Japan. However, the impact of these newly approved drugs on survival in the real-world
Autor:
Toru Kadono, Hirokazu Shoji, Hidekazu Hirano, Natsuko Okita Okita, Satoru Iwasa, Atsuo Takashima, Ken Kato
Publikováno v:
Journal of Clinical Oncology. 41:438-438
438 Background: Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein which is associated with cancer growth. Overexpression of TROP2 in advanced gastric cancer (AGC) is known as a poor prognostic factor. However, the association
Autor:
Yuri Yoshinami, Hiroki Osumi, Atsuo Takashima, Ryoichi Sawada, Kota Ouchi, Takeru Wakatsuki, Akira Ooki, Izuma Nakayama, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hidekazu Hirano, Hirokazu Shoji, Natsuko Okita Okita, Narikazu Boku, Ken Kato, Naoki Ishizuka, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
Journal of Clinical Oncology. 41:206-206
206 Background: The ’’Neo RAS’’ phenomenon, in which tissue rat sarcoma viral oncogene homolog ( RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorectal cancer (mCRC), is gaining attention because epid
Autor:
Kai Tsugaru, Narikazu Boku, Chie Kudo-Saito, Hirokazu Shoji, Hiroshi Imazeki, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Naohiro Okano, Yukiya Narita, Yoshiyuki Yamamoto, Rika Kizawa, Kengo Nagashima, Kazunori Aoki, Kei Muro
Publikováno v:
Journal of Clinical Oncology. 41:425-425
425 Background: Blocking immune checkpoint (IC) pathways, particularly mediated by PD1 and PDL1, has attracted great attention as a promising strategy for treating gastrointestinal cancer. However, the clinical responses are low in many cases, and th
Autor:
Seiichiro Mitani, Yosuke Kito, Kaori Hino, Kentaro Kawakami, Naoki Izawa, Fumiyasu Hanamura, Yoshiyuki Yamamoto, Hirokazu Shoji, Azusa Komori, Shogen Boku, Kenji Tsuchihashi, Eishi Baba, Kyoko Kato, Yoshikane Nonagase, Toshihiko Matsumoto, Mitsuhiro Furuta, Hisato Kawakami
Publikováno v:
Journal of Clinical Oncology. 41:114-114
114 Background: Several guidelines recommended less intensive chemotherapy for vulnerable patients (pts) with metastatic colorectal cancer (mCRC). However, data in a real-world setting are insufficient particularly for second- or later-line therapies